On October 2, 2018, DNA Script, which describes itself as "the global leader in the development of enzymatic DNA synthesis," announced that it has successfully synthesized the world's first 150-nucleotide (nt) strand of DNA by de novo enzymatic synthesis. DNA Script's enzymatic approach reaches up to 99.5 percent efficacy for each nucleotide added, achieving parity with traditional chemical synthesis. DNA Script shared these results during a presentation at SynBioBeta 2018 (https://2018.synbiobeta.com/) — the premier conference for synthetic biology, held in San Francisco. "The technology developed by DNA Script is now on par with the performance of current commercial solutions done with the aid of phosphoramidite reagents. DNA Script is the first organization — commercial or academic — to demonstrate the feasibility of enzymatic DNA synthesis, proving the incredible potential of this nascent technology. In May, we announced a world-first with the enzymatic synthesis of a 50-nt strand of DNA, and we have been able to triple our performance in just four months. By 2019, we expect to be able to synthesize DNA strands several hundred nucleotides in length. The speed at which our enzymatic synthesis technique has progressed — from a single incorporation to 150 nt in just four years — significantly outperforms the historical trend for phosphoramidite chemistry." said Thomas Ybert, PhD, CEO, and Co-Founder of DNA Script. In the experiments routinely run by the R&D team at DNA Script, sequences of the four natural nucleotides are randomly generated in silico and then automatically synthesized in vitro on the hardware platform developed by the company, without any physical template. Dr. Ybert added: "This is only the beginning. Our goal is now to go way beyond chemistry.
Login Or Register To Read Full Story